Ultragenyx Pharmaceutical Inc. (RARE)
$
35.03
+0.68 (1.94%)
Key metrics
Financial statements
Free cash flow per share
-4.2896
Market cap
3.3 Billion
Price to sales ratio
5.6147
Debt to equity
0.2653
Current ratio
2.3971
Income quality
0.7095
Average inventory
45.5 Million
ROE
-1.8649
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ultragenyx Pharmaceutical Inc. is a prominent biopharmaceutical company that focuses on the identification, acquisition, development, and commercialization of novel products for treating rare and ultra-rare genetic diseases across North America, Europe, and internationally. The company reported selling, general, and administrative expenses of $321,610,000.00 indicating its operational overhead costs. Additionally, the company incurred an income tax expense of $1,597,000.00 reflecting its tax obligations. The total costs and expenses for the company are $1,096,203,000.00 which highlights its overall spending on various initiatives. Notably, the operating income ratio is -$0.96 showcasing the company's operational profitability margin. Furthermore, the company reported depreciation and amortization expenses of $35,543,000.00 indicating the wear and tear on its assets. Its biologic products include innovative treatments such as Crysvita (burosumab) for X-linked hypophosphatemia, Mepsevii for Mucopolysaccharidosis VII, and Dojolvi for long-chain fatty acid oxidation disorders, among others. The company's pipeline also features promising candidates like DTX401 for glycogen storage disease type Ia and UX143 for osteogenesis imperfecta. The stock is affordable at $ 35.03 making it suitable for budget-conscious investors. With an average trading volume of 922,193.00 the stock exhibits moderate liquidity, ensuring that investors can buy and sell shares with relative ease. Ultragenyx operates with a mid-range market capitalization of $ 3,311,806,260.00 defining the company as a steady performer within the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape through its innovative therapies. Additionally, the company belongs to the Healthcare sector, driving innovation and growth in a competitive environment. Through collaboration and strategic partnerships, Ultragenyx continues to advance its mission to improve the lives of those affected by rare genetic diseases.
Is Ultragenyx Pharmaceutical Inc. (RARE) a good investment?
Investing in Ultragenyx Pharmaceutical Inc. (RARE) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C, with a Bearish outlook. Always conduct your own research before investing.
What is Ultragenyx Pharmaceutical Inc. (RARE)'s stock forecast?
Analysts predict Ultragenyx Pharmaceutical Inc. stock to fluctuate between $29.59 (low) and $60.37 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ultragenyx Pharmaceutical Inc.'s market capitalization?
As of 2025-05-29, Ultragenyx Pharmaceutical Inc.'s market cap is $3,311,806,260, based on 94,542,000 outstanding shares.
How does Ultragenyx Pharmaceutical Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Ultragenyx Pharmaceutical Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ultragenyx Pharmaceutical Inc. (RARE) stock?
To buy Ultragenyx Pharmaceutical Inc. (RARE) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for RARE. Place an order (Market, Limit, etc.).
What is the best time to invest in Ultragenyx Pharmaceutical Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Ultragenyx Pharmaceutical Inc. perform in the last earnings report?
Revenue: $560,230,000 | EPS: -$6.29 | Growth: -23.76%.
Where can I find Ultragenyx Pharmaceutical Inc.'s investor relations reports?
Visit https://www.ultragenyx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ultragenyx Pharmaceutical Inc.?
You can explore historical data from here
What is the all-time high and low for Ultragenyx Pharmaceutical Inc. stock?
All-time high: $175 (2021-02-10) | All-time low: $29.59 (2025-04-09).
What are the key trends affecting Ultragenyx Pharmaceutical Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
NOVATO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2024 Impact Report today, which covers the company's approach to corporate responsibility. The report highlights efforts to transform the lives of individuals and families affected by rare diseases, empower its employees, and make a meaningful impact on the communities it operates within and serves.
globenewswire.com
HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY HIGHLY COLLECTIBLE NSX-R TO FEATURE IN INAUGURAL BROAD ARROW CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION ON 24-25 MAY
zacks.com
RARE reports weaker-than-expected first-quarter results, as earnings and revenues miss estimates despite a year-over-year increase in product sales.
seekingalpha.com
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call Transcript
seekingalpha.com
Ultragenyx shows strong revenue growth and disciplined expense management, making it a compelling long-term investment despite inherent biotechnology risks. The company's diverse revenue streams from Crysvita, Dojolvi, and Evkeeza fund innovation and buffer against financial volatility. Key catalysts include the FDA's Priority Review of UX111 for Sanfilippo syndrome type A, with a PDUFA date set for August 2025.
globenewswire.com
Broad Arrow Auctions, a Hagerty (NYSE: HGTY) company, has announced an exceedingly rare 1989 RUF CTR Yellowbird, chassis no. W09BT0348KPR06023, to lead its second annual Porsche Auction in partnership with Air|Water. Set for April 26 at the Orange County Fairgrounds in Costa Mesa, California, the single-day auction held within the Air|Water event will once again feature more than 50 desirable Porsches along with a selection of coveted Porsche memorabilia pieces.
globenewswire.com
NOVATO, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced participation in three upcoming investor conferences.
globenewswire.com
VANCOUVER, BC, Feb. 18, 2025 (GLOBE NEWSWIRE) -- AMERICAN SALARS LITHIUM INC. ("AMERICAN SALARS" OR THE "COMPANY") (CSE: USLI, OTC: USLIF, FWB: Z3P, WKN: A3E2NY ) announces that it has entered into a share purchase agreement to acquire all of the outstanding shares of 1447377 BC Ltd. (the “Vendor”) that holds a 100% interest in a highly prospective 18,083 Hectares (180 sq km) Hardrock LCT (“Lithium-Cesium-Tantalum”) Pegmatite Project including Rare Earth Elements (“REE”) and a suite of Critical Minerals (the “Jaguaribe Project”).
zacks.com
RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.
seekingalpha.com
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q4 2024 Earnings Conference Call February 13, 2025 5:00 PM ET Company Participants Joshua Higa - VP, IR Emil Kakkis - CEO and President Erik Harris - CCO Howard Horn - CFO Eric Crombez - CMO Conference Call Participants Tazeen Ahmad - Bank of America Salveen Richter - Goldman Sachs Gena Wang - Barclays Yaron Werber - TD Cowen Joon Lee - Truist Securities Jeff Hung - Morgan Stanley Rick Miller - Cantor Fitzgerald Luca Issi - RBC Capital Liisa Bayko - Evercore ISI Operator Good afternoon, and welcome to the Ultragenyx Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in a listen-only-mode.
See all news
